Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

Autor: Özgecan Dülgar, Başak Bala Öven, Muhammed Mustafa Atcı, Rukiye Arıkan, Seval Ay, Murat Ayhan, Oğuzhan Selvi, Deniz Tataroglu Ozyukseler, Ertuğrul Bayram, Erkan Özcan, Ayşe İrem Yasin, Mahmut Gümüş

Publikováno v: Expert Review of Anticancer Therapy. 22:773-780

Background Triple-negative-breast-cancer (TNBC) has a poor prognosis if pathologic complete response (pCR) cannot be achieved following neoadjuvant chemotherapy (NAC). The group of patients that benefit most from adjuvant capecitabine remains unclear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0571c521d2d9822c93b445b5fe9351bd
https://doi.org/10.1080/14737140.2022.2076670

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.

Autor: Arikan R; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Ozguven S; Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey., Telli TA; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Isik S; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Demircan NC; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Basoglu T; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Yasar A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Celebi A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Filizoglu N; Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey., Ustun HS; Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey., Tinay I; Department of Urology, Marmara University School of Medicine, Istanbul, Turkey., Ones T; Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey., Turoglu HT; Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey., Erdil TY; Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey., Ozturk MA; Department of Internal Medicine, Division of Medical Oncology, Bahcesehir University School of Medicine, Istanbul, Turkey., Ercelep O; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Bayoglu V; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Kostek O; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Dane F; Department of Internal Medicine, Division of Medical Oncology, Acıbadem University School of Medicine, Istanbul, Turkey., Yumuk PF; Department of Internal Medicine, Division of Medical Oncology, Koc University School of Medicine, Istanbul, Turkey.

Publikováno v: Acta radiologica (Stockholm, Sweden : 1987) [Acta Radiol] 2023 May; Vol. 64 (5), pp. 2040-2049. Date of Electronic Publication: 2022 Nov 29.

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens.

Autor: Arikan R; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Atci MM; Department of Internal Medicine, Division of Medical Oncology, Professor Dr Cemil Tascioglu City Hospital, Istanbul 34384, Turkey., Ay S; Department of Internal Medicine, Division of Medical Oncology, Medeniyet University, School of Medicine, Istanbul 34722, Turkey., Ayhan M; Department of Internal Medicine, Division of Medical Oncology, Istanbul Kartal Lutfi Kirdar Education and Training Hospital, Istanbul 34865, Turkey., Demircan NC; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Telli TA; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Çelebi A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Yaşar A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Işik S; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Celikel C; Department of Pathology, Marmara University School of Medicine, Istanbul 34899, Turkey., Balvan O; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Bayoglu IV; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Kostek O; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Dane F; Department of Internal Medicine, Division of Medical Oncology, Acıbadem University School of Medicine, Istanbul 34758, Turkey., Yumuk PF; Department of Internal Medicine, Division of Medical Oncology, Koc University School of Medicine, Istanbul 34010, Turkey.

Publikováno v: Oncology letters [Oncol Lett] 2023 Apr 05; Vol. 25 (5), pp. 208. Date of Electronic Publication: 2023 Apr 05 (Print Publication: 2023).